Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL29273642 | 0.91 | ALDH1A1 (0.32) | UCHL1ALDH1A1 | |
| SCHEMBL19523853 | 0.86 | UCHL1 (0.31) | UCHL1 | |
| SCHEMBL25406099 | 0.81 | FFAR1 (0.33) | FFAR1UCHL1LPLLIPGP2RX7 | |
| SCHEMBL21227564 | 0.80 | LPL (0.36) | FFAR1LPLLIPGP2RX7 | |
| SCHEMBL26674805 | 0.80 | FFAR1 (0.33) | FFAR1LPLLIPGP2RX7 | |
| SCHEMBL18390323 | 0.77 | FFAR1 (0.31) | FFAR1 | |
| SCHEMBL18390326 | 0.77 | FFAR1 (0.37) | FFAR1 | |
| SCHEMBL18125388 | 0.77 | SMN1; SMN2 (0.38) | FFAR1UCHL1COMTLPLLIPG | |
| SCHEMBL20481588 | 0.77 | FFAR1 (0.31) | FFAR1 | |
| SCHEMBL15885885 | 0.77 | FFAR1 (0.34) | FFAR1UCHL1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2010-05-13 | — | — | US | disclosed |
| WO-2010051373-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | FFAR1 305/4885UCHL1 1218/4885COMT 111/4885 |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | FFAR1 3286/4885UCHL1 4461/4885COMT 620/4885 |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | FFAR1 1378/4885UCHL1 1264/4885COMT 1/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | FFAR1 3516/4885UCHL1 4087/4885COMT 2584/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | FFAR1 898/4885UCHL1 4221/4885COMT 4772/4885 |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | FFAR1 484/4885UCHL1 2647/4885COMT 2172/4885 |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | FFAR1 3388/4885UCHL1 1360/4885COMT 1621/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | FFAR1 1016/4885UCHL1 3067/4885COMT 3979/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | FFAR1 3749/4885UCHL1 2588/4885COMT 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.